SOURCE: TOPIGEN Pharmaceuticals, Inc.

November 29, 2007 08:01 ET

TOPIGEN to Participate in BMO and RBC Healthcare Conferences

Company to Provide Updates on Clinical Progress With Lead Programs

MONTREAL--(Marketwire - November 29, 2007) - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory diseases, today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will participate in the BMO Capital Markets Focus on Healthcare Conference and the RBC Capital Markets 2007 Healthcare Conference, both to be held in New York, NY. Dr. Wotton will be available for one-on-one meetings during both conferences.

Privately held, TOPIGEN is focused on the global respiratory care market and is developing new classes of inhaled drugs to meet that market's high unmet need for innovative therapies. The company's lead products, TPI 1020 and TPI ASM8, have completed initial Phase 2 studies with positive therapeutic results. TPI 1020 is a novel, inhaled anti-inflammatory compound with a unique mechanism of action. It has the potential to halt disease progression and improve morbidity/mortality in chronic obstructive pulmonary disease (COPD). TPI ASM8, which is based on TOPIGEN's proprietary mRNA-silencing technology, inhibits multiple pathways responsible for lung inflammation in asthma. TPI ASM8 has been proven to be effective in a Phase 2 study in mild to moderate asthma.

Presentation Information

The BMO Capital Markets Focus on Healthcare Conference will be held at the Millennium Broadway Hotel from December 4 - 5, 2007. Dr. Wotton will present on December 5, 2007 at 10:30 AM.

The RBC Capital Markets 2007 Healthcare Conference will take place at the Westin New York Hotel at Times Square from December 12 - 13, 2007. Dr. Wotton will participate in a panel presentation titled, "Effectively Addressing Challenges," on Wednesday, December 12, 2007 from 9:00 AM - 9:55 AM.


TOPIGEN is a privately held, clinical-stage company focused on developing new classes of inhaled drugs for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. TOPIGEN is actively progressing two drug candidates in Phase 2 trials for COPD and asthma, including TPI 1020, a novel anti-inflammatory, licensed from NicOx S.A. and TPI ASM8, which utilizes its proprietary mRNA-silencing technology. These drug candidates target multiple pathways and pro-inflammatory mediators involved in chronic pulmonary diseases.

Current venture investors include: NovaQuest, MMV Financial, Inc., BDC Venture Capital, Fonds de solidarité FTQ, Desjardins Venture Capital, Caisse de Dépôt et Placement du Québec (Caisse), T2C2/BIO 2000 and Lothian Partners 27 (sarl) SICAR. For more detailed information on TOPIGEN visit

Contact Information

  • Corporate Contact:
    Paul K. Wotton, Ph.D.
    TOPIGEN Pharmaceuticals, Inc.
    (514) 868-0404
    Email Contact

    IR/PR Contact:
    Tim Allison
    LaVoie Group
    (978) 745-4200 X102
    Email Contact